Amedisys Inc (AMED)
Working capital turnover
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 2,236,382 | 2,227,658 | 2,229,409 | 2,234,331 | 2,223,199 | 1,671,704 | 1,667,201 | 1,111,979 | 573,337 | 567,158 | 15,793 | 33,153 | 518,223 | 1,014,511 | 1,507,022 | 1,979,978 | 1,955,633 | 1,889,333 | 1,810,011 | 1,726,487 |
| Total current assets | US$ in thousands | 496,935 | 467,227 | 426,544 | 405,557 | 388,961 | 388,780 | 394,869 | 392,485 | 356,684 | 432,882 | 390,965 | 380,450 | 361,984 | 411,250 | 449,540 | 468,128 | 350,554 | 299,519 | 275,785 | 271,731 |
| Total current liabilities | US$ in thousands | 473,721 | 468,119 | 462,401 | 353,050 | 355,529 | 367,200 | 427,372 | 380,154 | 374,282 | 454,349 | 449,223 | 456,082 | 456,337 | 437,496 | 442,048 | 316,106 | 326,943 | 314,653 | 313,007 | 297,377 |
| Working capital turnover | 96.34 | — | — | 42.55 | 66.50 | 77.47 | — | 90.18 | — | — | — | — | — | — | 201.15 | 13.02 | 82.83 | — | — | — |
December 31, 2023 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $2,236,382K ÷ ($496,935K – $473,721K)
= 96.34
The working capital turnover ratio of Amedisys Inc. fluctuated over the past eight quarters, ranging from a low of 42.55 in Q1 2023 to a high of 180.21 in Q1 2022. This ratio measures the efficiency with which the company utilizes its working capital to generate revenue, with a higher ratio indicating better efficiency.
In Q4 2022, the ratio was 66.50, indicating that for every $1 of working capital, the company generated $66.50 of revenue. This ratio increased to 102.89 in Q3 2022, reflecting improved working capital efficiency. However, in Q4 2023, the ratio significantly rose to 96.34, suggesting a potential decline in efficiency compared to the previous quarters.
The absence of data for Q3 2023 and Q2 2023 limits a comprehensive trend analysis. It is important to monitor future quarters to assess the consistency and sustainability of Amedisys Inc.'s working capital management efficiency.
Peer comparison
Dec 31, 2023